Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

Tenaya Therapeutics plans investor meetings and an on-demand fireside chat around two major September 2026 healthcare investment conferences.

Rhea-AI Summary

Tenaya Therapeutics (TNYA) will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Company management will host investor meetings at both events.

A fireside chat from the H.C. Wainwright conference will be available on demand from September 11, 2026, via the Investors section of Tenaya’s website and will remain archived for about 30 days.

Market Context

The August 4 investor-conference notice preceded a 5.81% 24-hour move, providing a direct precedent ...

Analysis

The August 4 investor-conference notice preceded a 5.81% 24-hour move, providing a direct precedent for this scheduling announcement. Recent insider activity was Net Selling; new clinical or financial disclosures remained the key item to watch.

Key Figures

H.C. Wainwright conference edition: 28th Annual H.C. Wainwright conference date: September 14, 2026 Morgan Stanley conference edition: 24th Annual +3 more

6 metrics

H.C. Wainwright conference edition 28th Annual H.C. Wainwright Global Investment Conference

H.C. Wainwright conference date September 14, 2026 Investor meetings

Morgan Stanley conference edition 24th Annual Morgan Stanley Global Healthcare Conference

Morgan Stanley conference date September 15, 2026 Investor meetings

Fireside chat availability September 11, 2026 On-demand access begins at 7:00 AM ET

Archive period 30 days Following the H.C. Wainwright conference

Historical Context

5 past events · Latest: Aug 05 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 05	Q2 earnings report	Negative	-7.5%	Higher net loss and impairment charge accompanied pipeline and cash runway updates.
Aug 04	Investor conference participation	Neutral	+5.8%	Management meetings and a fireside chat were scheduled at an investment conference.
Jul 14	Inducement equity grants	Negative	-2.5%	Stock options covering 1,837,200 shares were granted to new employees.
Jun 29	CFO appointment	Positive	+2.4%	Eric Hyllengren became CFO effective July 13, 2026, following finance leadership experience.
Jun 03	Phase 1b/2 clinical data	Positive	-0.5%	Interim TN-201 data showed cardiac and symptom improvements without dose-limiting toxicities.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Reactions varied: the prior conference-participation announcement preceded a 5.81% gain, while earnings and clinical updates had negative reactions.

Key Terms

gene therapy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, HDAC6 inhibitor, +1 more

5 terms

gene therapy medical

"TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

hypertrophic cardiomyopathy medical

"MYBPC3-associated hypertrophic cardiomyopathy (HCM)"

Hypertrophic cardiomyopathy is a genetic heart condition in which the heart muscle becomes abnormally thick, making it harder for the heart to pump and for electrical signals to travel normally; think of a pump whose walls have thickened so it moves less efficiently. Investors care because the condition drives demand for diagnostics, drugs and devices, affects workforce and insurance costs, and can influence clinical trial results, regulatory approvals and liability exposure in healthcare-related companies.

arrhythmogenic right ventricular cardiomyopathy medical

"PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC)"

A hereditary heart condition in which muscle in the right pumping chamber is gradually replaced by fat or scar tissue, disrupting the heart’s electrical signals and causing abnormal rhythms that can lead to fainting or sudden cardiac arrest. Investors should care because it drives demand for diagnostics, devices (like implanted defibrillators), drugs and long-term care, affects clinical trial size and regulatory risk, and can influence healthcare costs and market opportunities for related companies.

HDAC6 inhibitor medical

"a highly specific small molecule HDAC6 inhibitor"

An HDAC6 inhibitor is a drug that blocks the activity of the HDAC6 enzyme, which helps control how cells manage certain proteins and switch genes on or off. Think of HDAC6 as a combination of a light switch and a cleaning crew inside cells; inhibiting it can change cell behavior and reduce harmful protein buildup. Investors care because this mechanism underlies potential treatments for cancers, neurodegenerative and inflammatory diseases, so it shapes clinical risk, development timelines and market opportunity.

heart failure with preserved ejection fraction medical

"including heart failure with preserved ejection fraction (HFpEF)"

A form of heart disease where the heart muscle pumps out a normal share of blood each beat but struggles to relax and fill properly, like a pump that can push water out but has trouble drawing enough back in between cycles. It matters to investors because it drives large and growing demand for treatments, hospital care and diagnostic tests, influences clinical trial design and regulatory decisions, and can affect the commercial prospects of drugs and medical devices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will host investor meetings at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026 and the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026.

A fireside chat from the H.C. Wainwright 28th Annual Global Investment Conference will be available on demand beginning Friday, September 11, 2026, at 7:00 AM ET and may be accessed from the Investors section of Tenaya’s website, where it will be archived for approximately 30 days following the conference.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.

Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com

Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com

FAQ

When will Tenaya Therapeutics (TNYA) attend investor conferences in September 2026?

Tenaya Therapeutics is scheduled to host investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, and at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.

How can investors access Tenaya Therapeutics’ fireside chat from the H.C. Wainwright conference?

The fireside chat will be available on demand starting September 11, 2026, at 7:00 AM ET. It may be accessed through the Investors section of Tenaya Therapeutics’ website and will be archived there for approximately 30 days.

Which conferences will Tenaya Therapeutics (TNYA) participate in during September 2026?

Tenaya Therapeutics will participate in the H.C. Wainwright 28th Annual Global Investment Conference and the Morgan Stanley 24th Annual Global Healthcare Conference, hosting investor meetings at both events.

What type of company is Tenaya Therapeutics (TNYA) and what is its clinical focus?

Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing and delivering potentially curative therapies that address the underlying causes of heart disease, including rare genetic cardiomyopathies and more prevalent heart conditions.

What drug candidates are in Tenaya Therapeutics’ pipeline mentioned in this announcement?

Tenaya’s pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, and TN-301, an HDAC6 inhibitor for cardiac, metabolic and muscular conditions such as HFpEF and DMD.